Non-invasive screening Intus Bio is actively developing non-invasive colorectal cancer screening leveraging high-resolution microbiome analytics, presenting a direct sales opportunity to biomedical researchers, hospitals, and diagnostic labs seeking novel early-detection tools.

NIH/NCI funding Recent NIH/NCI Fast-Track funding for bacteria-based early-onset colorectal cancer tests signals potential procurement and collaboration opportunities with funded programs, clinical researchers, and translational partners looking for scalable microbiome solutions.

GutID expansion The launch of GutID and related microbiome testing capabilities suggests upsell potential to clinics, consumer-facing health platforms, and patient advocacy groups seeking actionable microbiome reports and consumer diagnostics.

Strategic acquisitions Acquisition of Pattern Genomics indicates a capability uplift in genomic software and analysis tools, enabling cross-sell of integrated Titan-1 platform services to pharma, diagnostics, and contract research organizations requiring end-to-end microbiome solutions.

Cross-industry reach With customers across pharmaceutical, diagnostic, testing, health, agriculture, and environmental sectors, there are diversified sales lanes for partnerships, licensing, and enterprise deals that combine research services with platform-based analytics.